Unipharma Co., Ltd.
TTPEX:662111.55
TWD
+0.50
(+4.52%)
Unipharma Co., Ltd.
TPEX:6621
(Taipei Exchange)
Recent
price
11.55
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.- Similar Companies
- Business
- UniPharma Co., Ltd. engages primarily in the marketing and distribution of pharmaceutical drugs, medical devices, and diagnostic tests across Taiwan. Its core product portfolio includes diagnostic reagents for cancer and disease detection, with particular focus on six medical specialties: colorectal surgery, obstetrics and gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company offers products such as Adept anti-adhesion solutions, bain/esmolol HCl/naloxone anesthesia injections, Elisa DR-70 in-vitro diagnostic tumor tests, and fomeject antidote injections. In addition to pharmaceuticals and diagnostics, UniPharma provides medical technology services, research and development, and clinical trial support. Its client base includes major medical centers, regional and local hospitals, and clinics, ensuring broad market access across Taiwan. Founded in 1965 and headquartered in Taipei, UniPharma is advancing in three key areas: pharmaceuticals, medical devices, and medical technology services. It has also expanded actively into regenerative medicine solutions, focusing on innovative equipment and treatment options supported by full pre-sales and after-sales technical assistance. Recent strategic developments include acquiring exclusive distribution rights to CASTOMIZE, a Singapore-developed customizable orthopedic cast solution, expected to launch expanded models in late 2025. This complements its earlier success marketing Baxter Healthcare’s Adept anti-adhesion solution, demonstrating ongoing efforts to broaden its advanced medical device offerings. UniPharma has been engaged in partnerships and business expansions to strengthen its market position, including collaborations with international pharmaceutical companies and continuous investment in innovation and R&D to enhance its product quality and service range. Its forward-looking strategy emphasizes marketing expansion and international collaborations to diversify its product portfolio and drive growth. UniPharma retains a significant presence in Taiwanese healthcare markets while extending its reach in the regenerative medicine field. As of mid-2025, a major shareholder, Saudi Arabia-based Jadwa Investment Co., has been preparing to divest its 51% stake in the company, reflecting evolving ownership dynamics. In summary, UniPharma Co., Ltd. provides a comprehensive array of pharmaceuticals, diagnostic reagents, and medical devices with a specialty in cancer-related diagnostics and surgical aids. It complements its product suite with advanced regenerative medicine solutions and orthopedic devices. The company continues to evolve through strategic partnerships, exclusive distribution agreements, and investment in innovative technologies, maintaining a strong footprint in Taiwan's healthcare sector and aiming for broader international engagement. This description reflects information current as of late 2025 from company disclosures and market reports.